David Missimo
Psychiatry · Plano, TXNPI 1184842064
Payments from drug & device makers
Across 319 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Corium, LLC$616
- AbbVie$607
- Otsuka America Pharmaceutical, Inc.$582
- Takeda Pharmaceuticals U.S.A., Inc.$556
- Johnson & Johnson$390
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,719100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 68 | $1,253 |
| Corium, LLC | 27 | $616 |
| AbbVie(2 entities) | 38 | $607 |
| Otsuka America Pharmaceutical, Inc. | 33 | $582 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $556 |
| Johnson & Johnson | 22 | $390 |
| Neos Therapeutics, LP | 22 | $365 |
| Supernus Pharmaceuticals, Inc. | 12 | $221 |
| Bausch Health US, LLC | 10 | $196 |
| Tris Pharma Inc | 14 | $148 |
| Axsome Therapeutics, Inc. | 5 | $110 |
| Sunovion Pharmaceuticals Inc. | 6 | $109 |
| Adlon Therapeutics L.p. | 6 | $103 |
| Jazz Pharmaceuticals Inc. | 5 | $99 |
| Shire North American Group Inc | 4 | $77 |
| Noven Therapeutics, LLC | 3 | $56 |
| Idorsia Pharmaceuticals US Inc | 2 | $44 |
| Vertical Pharmaceuticals, LLC | 2 | $44 |
| Ironshore Pharmaceuticals Inc. | 1 | $43 |
| Almatica Pharma LLC | 2 | $38 |
| Neuronetics, Inc. | 2 | $34 |
| Avion Pharmaceuticals | 1 | $23 |
| Alkermes, Inc. | 1 | $13 |
How this compares
$5,725 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 22 | $11,955 |
| AmbienZolpidem Tartrate | 12 | $7,665 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 126 | $4,286 |
| Lisdexamfetamine Dimesylate | 18 | $3,971 |
| Bupropion XlBupropion Hcl | 104 | $2,145 |
| Duloxetine Hcl | 91 | $1,828 |
| Escitalopram Oxalate | 172 | $1,672 |
| Clonazepam | 123 | $1,643 |
| Zolpidem Tartrate | 95 | $1,101 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $933 |
| Eszopiclone | 55 | $893 |
| Zolpidem Tartrate ErZolpidem Tartrate | 15 | $750 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $725 |
| Doxepin Hcl | 13 | $667 |
| Lorazepam | 139 | $597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $556 | $11,95522 claims |
| Almatica Pharma LLCSertraline Hcl | $38 | $37654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Plano
- Suresh SureddiPlano$5.9M
- Sejal MehtaPlano$3.3M
- David CrumpackerPlano$386K
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.